Navigation Links
Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
Date:10/4/2010

HARBIN, China, Oct. 4 /PRNewswire-Asia-FirstCall / -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company intends to launch three new therapeutics during the first quarter of 2011.  Weikang expects that its new products have the potential to add up to approximately $3.1 million in revenue and up to approximately $1.1 million in net income combined in 2011.  

"We are pleased to be able to regularly launch high margin new products that enable us to continue expanding our market penetration and future revenue and net income growth," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Over the past few years our research and development team have been extremely focused on developing a strong pipeline of high-quality, therapeutics to address today's important health issues. In addition, we ensure that our products are produced using the highest quality of natural ingredients and advanced processing technologies for maximum effectiveness."

The new therapeutics have been approved by the State Food and Drug Administration (SFDA).  A brief description of the new therapeutics expected to be launched in first quarter 2011 is listed below:

TiangFang

  • Shouwu Long Life is primarily used to strengthen kidney and cardiovascular system, as well as improve blood circulation in mature adults.  It is also beneficial in treating dizziness, ringing in the ears, forgetfulness, and early graying.

  • Lysozyme Buccal is an antibiotic tablet which can effectively treat the acute and chronic pharyngitis, upper respiratory infections and ulceration symptoms.

  • Rongrun

  • Ha Ge Jiao Lan is used to treat symptoms associated with menopause as well as increase youthful vitality and balance hormones.

  • About Weikang Bio-Technology Group Co., Inc.Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang.  For more information, please visit http://www.weikangbio.com.

    Safe Harbor StatementThis press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.Company contact:Ren Hu, VP of FinanceWeikang Bio-Technology Group Co., Inc.US Tel: (201) 887-0415China cell: 13718728163Email: rhu@weikangbio.comInvestors Relation contacts:John Marco, Partner, Elite IRTel:   +1-310-819-2948Email: John.marco@elite-ir.comLeslie J. Richardson, Partner, Elite IRTel:   +852-3183-0283Email: Leslie.richardson@elite-ir.com
    '/>"/>

    SOURCE Weikang Bio-Technology Group Co., Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
    2. Weikang Bio-Technology Announces Filing for NASDAQ Listing
    3. Weikang Bio-Technology Reports First Quarter 2010 Financial Results
    4. Texas Health Plans Implementing Cost-Sharing From Employers to Employees by Focusing on Increasing Generic Utilization
    5. Colleen Goggins, Worldwide Chairman, Consumer Group Plans Retirement From Johnson & Johnson in Early 2011
    6. OrthoAccel Technologies Committed to Plans for Positioning the United Kingdom as a Key Strategic Market for New Orthodontic Technology
    7. Volcano Announces Plans to Introduce Multiple New Products at EuroPCR 2010
    8. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
    9. UBM Announces Plans for Japan Pharma & Bio Events
    10. GeoVax Labs, Inc. Plans Public Offering
    11. As Biopharma Companies Reshape Sales Model, Most See Resetting Territory Size and Implementing Individualized Call Plans as First Steps Toward Change, According to New Research From Best Practices, LLC
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
    (Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
    (Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
    Breaking Medicine Technology:
    (Date:4/26/2017)... ... April 26, 2017 , ... CareSet Labs today is releasing ... measured in Part D Medicare data. The dataset, called PaPR (Providers and Prescribing ... faxes or paper. The PaPR (pronounced "paper") data set aggregates this information ...
    (Date:4/26/2017)... ... ... Miami native and local periodontist Dr. John Paul Gallardo is celebrating ... 1991 that this journey would have taken me into so many learning experiences both ... has pioneered implant dentistry innovation, evolving into an internationally recognized leader in the industry. ...
    (Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
    (Date:4/25/2017)... ... 25, 2017 , ... A stressful work environment can hurt the physical and ... and performance in the workplace. The goal of Clearview Resolution Services has always been ... April, Clearview Resolution Services will be shutting down the office early on Fridays. The ...
    (Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
    Breaking Medicine News(10 mins):